GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh2 Group Ltd (NAS:FRES) » Definitions » ROE % Adjusted to Book Value

Fresh2 Group (Fresh2 Group) ROE % Adjusted to Book Value : 0.00% (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Fresh2 Group ROE % Adjusted to Book Value?

Fresh2 Group's ROE % for the quarter that ended in Jun. 2023 was 0.00%. Fresh2 Group's PB Ratio for the quarter that ended in Jun. 2023 was 2.90. Fresh2 Group's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 was 0.00%.


Fresh2 Group ROE % Adjusted to Book Value Historical Data

The historical data trend for Fresh2 Group's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh2 Group ROE % Adjusted to Book Value Chart

Fresh2 Group Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
Get a 7-Day Free Trial - - - - -

Fresh2 Group Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -350.19 -188.77 - - -

Competitive Comparison of Fresh2 Group's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Fresh2 Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fresh2 Group's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh2 Group's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Fresh2 Group's ROE % Adjusted to Book Value falls into.



Fresh2 Group ROE % Adjusted to Book Value Calculation

Fresh2 Group's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Fresh2 Group's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 2.90
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fresh2 Group ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Fresh2 Group's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Fresh2 Group (Fresh2 Group) Business Description

Industry
Traded in Other Exchanges
Address
650 5TH Avenue, Street 2416, NEW YORK, NY, USA, 10019-6108
Fresh2 Group Ltd is a biotechnology company. It focuses on early cancer screening and detection. The company markets and sells a multi-cancer screening and detection test that uses its innovative patented CDA technology and its proprietary CDA device. In addition to early cancer screening and detection, its CDA technology has demonstrated the potential to assist physicians in cancer diagnosis, prognosis, and recurrence.